Business
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n LAS VEGAS, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026. \"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease,\" said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. \"This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics.\" For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled \"Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease\" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA). The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving \"relative\" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of c...